Consensus Pfizer, Inc.

Equities

PFE

US7170811035

Market Closed - Nyse Other stock markets 04:01:58 2024-05-28 pm EDT			After market 08:00:00 pm
28.3 ^USD	-2.01%		28.1	-0.71%

May. 27	US, European nations consider vaccinating workers exposed to bird flu	RE
May. 24	Novavax awaits FDA decision on whether its next COVID shot can be offered in US	RE

Evolution of the average Target Price on Pfizer, Inc.

Price target over the last 5 years

History of analyst recommendation changes

5b4a7d2c42bfef070da7a2c8.d-xN1S0oLFniGpTgbydrSp_YVJVft_KhVdNu8efCJ0I.J60Yj19kGCuVX_CCF0JTAqq-EeA947qUN-sjtNaYXSUknhy5bEMfFJAqxQ~e40a430f02eadfedbd92552e67ebb4fa

Analyst Recommendations on Pfizer, Inc.

DA Davidson Raises Price Target on Pfizer to $35 From $30, Maintains Buy/Add Rating	May. 20	MT
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program	May. 17	MT
Redburn Atlantic Adjusts Price Target on Pfizer to $27 From $26, Keeps Neutral Rating	May. 13	MT
PFIZER INC : Buy rating from DZ Bank	May. 02	ZD
Morgan Stanley Adjusts Price Target on Pfizer to $29 From $28	May. 02	MT
Leerink Adjusts Price Target on Pfizer to $29 From $27	May. 02	MT
BMO Capital Adjusts Pfizer's Price Target to $36 From $33, Keeps Outperform Rating	May. 02	MT
Morgan Stanley Lifts Price Target on Pfizer to $29 From $28, Keeps Equalweight Rating	May. 02	MT
PFIZER INC : Jefferies gives a Buy rating	May. 01	ZD
PFIZER INC : UBS remains Neutral	May. 01	ZD
PFIZER INC : JP Morgan remains Neutral	May. 01	ZD
Connect Biopharma Terminates Agreement on Antiallergic Candidate With Pfizer	Apr. 17	MT
Novavax Shareholder Shah Capital Pushes to Add 2 Nominees to Company's Board	Apr. 15	MT
PFIZER INC : JP Morgan remains Neutral	Apr. 12	ZD
Skanska Trims Scope of Work for Biomanufacturing Facility Project in US	Apr. 12	MT
PFIZER INC : Berenberg remains Neutral	Apr. 10	ZD
Argus Downgrades Pfizer to Hold From Buy	Mar. 22	MT
PFIZER INC : JP Morgan sticks Neutral	Mar. 07	ZD
PFIZER INC : JP Morgan sticks Neutral	Mar. 01	ZD
Guggenheim Initiates Pfizer With Buy Rating, Price Target is $36	Feb. 23	MT
China move leaves markets unfazed	Feb. 20
Indian shares set to open higher ahead of national budget	Jan. 31	RE
UBS Trims Pfizer Price Target to $28 From $29, Maintains Neutral Rating	Jan. 31	MT
PFIZER INC : UBS gives a Neutral rating	Jan. 31	ZD
PFIZER INC : Buy rating from Jefferies	Jan. 30	ZD

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

28.3 USD

Average target price

31.92 USD

Spread / Average Target

+12.78%

High Price Target

45 USD

Spread / Highest target

+59.01%

Low Price Target

27 USD

Spread / Lowest Target

-4.59%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Pfizer, Inc.

DA Davidson
Redburn Atlantic
Morgan Stanley
Leerink Partners
BMO Capital
DZ BANK	Elmar Kraus
JPMORGAN	Chris Schott
UBS	Trung Huynh
JEFFERIES	Akash Tewari
BERENBERG	Kerry Holford
Argus
Guggenheim
TD Cowen
JPMorgan Chase
Redburn
Wells Fargo Securities
Daiwa Securities
Truist Securities
Cantor Fitzgerald
Barclays
Jefferies & Co.
Goldman Sachs
Credit Suisse
SVB Securities LLC
HSBC
Berenberg Bank
BofA Securities
Atlantic Equities
Citigroup
Mizuho Securities
Atlantic Securities
SVB Leerink
Independent Research
RBC
RBC Capital Markets
J.P. Morgan Chase

Ratings for Pfizer, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar